Cornerstone Planning Group’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-501
Closed -$76.7K – 1180
2026
Q2
$76.7K Sell
501
-1
-0.2% -$150 0.01% 306
2026
Q1
$73K Buy
502
+181
+56% +$27.7K 0.01% 307
2025
Q4
$47.5K Buy
321
+319
+15,950% +$41.8K 0.01% 365
2025
Q3
$17 Sell
2
-166
-99% -$20.3K ﹤0.01% 1681
2025
Q2
$19.8K Buy
168
+49
+41% +$5.52K ﹤0.01% 420
2025
Q1
$13.1K Buy
119
+40
+51% +$4.26K ﹤0.01% 498
2024
Q4
$8.17K Sell
79
-36
-31% -$3.84K ﹤0.01% 472
2024
Q3
$12.7K Buy
115
+16
+16% +$1.82K ﹤0.01% 371
2024
Q2
$10.9K Buy
99
+54
+120% +$5.42K ﹤0.01% 421
2024
Q1
$4.38K Buy
+45
New +$4.61K ﹤0.01% 537
2023
Q4
– Sell
-15
Closed -$1.53K – 998
2023
Q3
$1.53K Hold
15
– – ﹤0.01% 712
2023
Q2
$1.51K Buy
+15
New +$1.5K ﹤0.01% 1252
2022
Q4
$16.5K Buy
+179
New +$15.1K 0.01% 479

Other funds holding NVS

Cornerstone Planning Group's NVS Position: Q3 2026 in Review

Cornerstone Planning Group sold out of Novartis (NVS) in Q3 2026, closing a stake of 501 shares — an estimated $76.7K sold.

Cornerstone Planning Group first reported a position in NVS in Q4 2022 and held it in 13 quarters. The position peaked at $76.7K in Q2 2026. 447 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Cornerstone Planning Group reported no remaining Novartis position as of Q3 2026 after selling out during the quarter.
  • Cornerstone Planning Group sold 501 Novartis shares in Q3 2026, an estimated $76.7K.
  • Cornerstone Planning Group first reported a position in Novartis in Q4 2022 and held it in 13 quarters.
  • Cornerstone Planning Group's Novartis position peaked at $76.7K in Q2 2026.
  • 447 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Cornerstone Planning Group's 13F filing for Q3 2026, filed 16 Oct 2026.